Anrs, Emerging Infectious Diseases

This study tested a combination of four drugs (asunaprevir, daclatasvir, ribavirin, and pegylated interferon) in 60 adults with hepatitis C genotype 4 who had not responded to standard treatment. The goal was to see if this stronger therapy could clear the virus completely, with …

This study tested a new two-step vaccine approach to protect HIV-infected adults from pneumococcal infections, a common cause of serious illness in this group. The standard vaccine often doesn't work well in people with lower immune cell counts. The study involved 212 participant…

This Phase 1 trial tested a new HIV vaccine in 68 healthy adults to see if it is safe and triggers an immune response. The vaccine uses a DNA-based approach combined with an HIV protein to train the body to fight the virus. While early results are encouraging, this is just the fi…

This study tested four different HIV vaccine combinations in 92 healthy volunteers at low risk of HIV infection. The goal was to see which combinations were safest and best at triggering an immune response. Researchers used a prime-boost approach, giving an initial vaccine follow…

This study tested two different schedules of an experimental HIV vaccine in 147 healthy adults to see which one triggers a stronger immune response. Volunteers received either three DNA shots followed by one booster, or two DNA shots followed by two boosters. The goal was to find…

This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce eno…

This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…

This study looked at whether people who had COVID-19 more than 5 months ago need only one dose of the Pfizer mRNA vaccine, instead of the usual two. It included 267 healthy adults aged 18-45 or 65 and older, some with prior infection and some without. Researchers measured antibod…

This study tests a combination of three HIV drugs (amprenavir, lopinavir, and ritonavir) in patients whose current treatments are no longer working. The goal is to see if this new mix can lower the amount of HIV in the blood over 26 weeks. Participants are HIV-positive adults who…

This study tested a once-daily combination of three HIV drugs (FTC, ddI, efavirenz) in 39 adults who had never taken HIV medication before. The goal was to see if this simpler, once-a-day pill routine worked well and had fewer side effects than older treatments. Participants had …

This trial compares a once-daily combination of three HIV drugs (emtricitabine, didanosine, and efavirenz) to the standard multi-pill regimen containing a protease inhibitor. The goal is to see if the simpler daily pill works just as well at keeping the virus undetectable, while …

This study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measur…

This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…

This study looked at whether providing mental health care to people who inject drugs can improve their mental health and reduce their risk of getting HIV or hepatitis C. Over 500 participants in Haiphong, Vietnam, received free psychiatric consultations, medications, and support …

This study tested whether people with well-controlled HIV can safely take their antiretroviral drugs only 4 days in a row each week, instead of every day. Over 600 adults with stable HIV participated. The main goal was to see if the 4-day schedule kept the virus suppressed just a…

This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…

This study followed 27 HIV-positive people with kidney failure who received a kidney transplant. All were on a three-drug HIV treatment including Raltegravir. The goal was to see how many had graft rejection within 6 months, using blood tests and kidney biopsies.

This study tested two different once-daily HIV medication combinations in 101 people who had just been infected with HIV-1. The goal was to see which combo better lowered the amount of hidden virus in immune cells after 48 weeks. Both treatments are standard HIV therapies, so thi…

This study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This study tested whether a single HIV drug, darunavir/ritonavir, could replace the usual combination therapy in pregnant women with well-controlled HIV. The goal was to prevent mother-to-child transmission without using a class of drugs called NRTIs. 91 pregnant women already on…

This study tested whether people with HIV who have high immune cell counts (CD4 above 500) can safely take antiretroviral drugs in 6-month cycles—6 months on treatment, then 6 months off—instead of taking them every day. The goal was to see if this approach could keep their immun…

This study tested a two-drug combination of raltegravir and etravirine in 170 adults with HIV who were at least 45 years old and already had the virus well-controlled. Participants switched from a standard three-drug regimen to this simpler two-pill combo. After 96 weeks, over 98…

This study tested a three-drug combination (raltegravir, emtricitabine, and tenofovir) as a first treatment for people with HIV-2, a less common form of HIV found mainly in West Africa. The goal was to see if this combination could control the virus better than standard treatment…

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…

This study looked at whether a lower daily dose of the HIV drug darunavir (400 mg instead of 800 mg) can keep the virus suppressed in people whose HIV is already well-controlled. The trial involved 100 adults with HIV who had undetectable viral loads for at least a year. The goal…

This phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…

This study tested whether a stronger tuberculosis (TB) treatment could save more lives in people with HIV and very weak immune systems. Over 1,300 hospitalized patients received either the standard TB drugs or an intensified version with higher doses of two key medicines, plus a …

This pilot study tested whether low-dose CT scans can help find lung cancer early in HIV-positive people who are heavy smokers. Researchers scanned 450 participants to see how many had lung cancer and what types were found. The goal was to learn if this screening method is useful…

This study looked at whether men who have sex with men (MSM) in Burkina Faso, Côte d'Ivoire, Mali, and Togo would accept and use PrEP (a daily or on-demand pill) to prevent HIV. Over 600 HIV-negative men at high risk took part, receiving regular check-ups, STI testing, and suppor…

This study tested whether a quarterly HIV prevention program is practical and helpful for men who have sex with men in four African countries. Over 800 men received regular check-ups, STI testing and treatment, counseling, and condoms. The goal was to see if this approach could l…

This large study in South Africa tested whether offering HIV treatment to everyone right after diagnosis, instead of waiting until their immune system weakened, could reduce new HIV infections across entire communities. Over 28,000 people from 22 communities took part. The idea i…

This study tested whether a simpler HIV drug combination (lopinavir/ritonavir alone) could safely prevent mothers from passing HIV to their babies during pregnancy, compared to the standard three-drug combo. About 105 pregnant women with well-controlled HIV took part. The goal wa…

This study tested two strategies to prevent sexually transmitted infections (STIs) in men who have sex with men and already take HIV PrEP. One group took doxycycline pills after unprotected sex, and another group received a meningitis vaccine (Bexsero). The goal was to see if the…

This early-stage trial tested whether a combination of two HIV-1 activators is safe for people with HIV subtype B who are on standard antiretroviral therapy and have undetectable virus levels. Nine men participated, and the study focused on tracking side effects. The goal was to …

This study followed 516 HIV-positive men who have sex with men over two years to track anal HPV infection and related lesions. Researchers used exams and anoscopy to see how often high-grade lesions appear or go away on their own. The goal is to gather evidence to better prevent …

This study investigates why the gut immune barrier remains damaged in people with HIV even after successful antiretroviral therapy. Researchers collected blood and intestinal biopsies from 80 participants to measure immune cells and inflammation. The goal is to understand why the…

This study looked at a genetic variation in the TLR7 gene, which helps the immune system detect viruses like HIV-1. Researchers compared 90 women—some with HIV and some without—to see if this gene difference is more common in infected women. The goal was to understand how this va…

This study looks at why HIV remains in the body even when standard treatment keeps virus levels undetectable in the blood. Researchers will take small tissue samples from the gut and blood of 30 HIV-positive adults on effective therapy. The goal is to understand how the virus per…

This study looked at 20 men with HIV who were stable on a common drug combination. Researchers took samples of blood, lymph nodes, rectal tissue, fat, and semen to measure how much of the drugs reached these areas. The goal was to understand why HIV can still hide in some tissues…